Literature DB >> 6252147

Transfer of cefotaxime in human milk and from mother to foetus.

D A Kafetzis, C V Lazarides, C A Siafas, P A Georgakopoulos, C J Papadatos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6252147     DOI： 10.1093/jac/6.suppl_a.135

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

Review 1.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 3.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

4.  Ceftazidime levels in human breast milk.

Authors:  J D Blanco; J H Jorgensen; Y S Castaneda; S A Crawford
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum.

Authors:  D A Kafetzis; D C Brater; J E Fanourgakis; J Voyatzis; P Georgakopoulos
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

6.  Pharmacokinetics of cefotaxime, moxalactam, and cefoperazone in the early puerperium.

Authors:  D Charles; B Larsen
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.